|
KMID : 0388019920030010061
|
|
Korean Journal Gynecologic Oncology and Colposcopy
1992 Volume.3 No. 1 p.61 ~ p.71
|
|
|
Clinical Significance of the Placental Proteins(B-hCG, SP1, PP10) in Trophoblastic Disease
|
|
정재근
김진우/배석년/송승규/한구택/이헌영
|
|
|
Abstract
|
|
|
In order to find out whether the serum levels of three placental proteins, human chorionic gonadotrpin β-subunit (β-hCG), Schwangershafts Protein 1(SP1) and placental protein 10(PP10), can be used for prediction of the response of chemotherapy
and
differential diagnosis of hydatidiform mole invasive mole and choriocarcinoma, we measured the circulating levels of three placental protein in 22 patients with hydatidiform mole, 25 patients with invasive mole and 25 patients with
choriocarcinoma
who
were registered and treated in Korean Research Institute of Trophoblastic Disease, Catholic University Medical College, Seoul, Korea.
Each group of patients was divided into high risk and low risk groups according to the modified Bagshawe's scoring system.
PP10, a new placental glycoprotein, was measured by a specific and sensitive double antibody radioimmunoassay in each in each serum sample.
Both SP1 β-hCG are thought to be mainly produced by syncytiotrophoblasts, so we measured the SP1/β-hCG ratio to eliminate the influence of the number of trophoblastic cells.
@ES The results were as follows.
@EN 1. The SP1/β-hCG ratio of each group was 18.6±12.69 and 3.6±0.62 in low and high risk group of hydatidifrom molepatients, 3.5±0.70 and 1.8±0.52 in low and high risk group invasive mole patients and 1.5±o.91 and 0.3±0.15 in low and high
risk
group of choriocarcinoma patients respectively. As being progressed the disease, the ratio was decreased (p<0.05) but there were no significant differences between high risk group of hydatidiform mole and low risk group of invasive mole, high
risk
group
of invasive mole and low risk group of choriocarcinoma.
2. Serum levels of pp10 were 26.4±12.50ng/ml and 3.5±1.3ng/ml in low and high risk group of hydatidigrom mole patients respectively. PP10 was not detected in invasive mole and choriocarcinoma patients.
3. The response to chemotherapy was better in the group with higher SP1/β-hCG ration than in the group with lower SP1/β-hCG ratio.
4. Differential diagnosis between high risk group of hydatidifrom mole and low risk group of invasive mole could be made by measuring the SP1/β-hCG ratio and serum levels of PP10.
From the above results, it is considered that the SP1/β-hCG ratio and serum level of PP10 can be helpful for predicting the prognosis of trophoblastic diseases, performing the appropriate chemotherapy and making differential diagnosis between
high
group of hydatidifrom mole and low risk group of invasive mole.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|
|